MGMT and glioblastoma: Methylation-specific PCR enables the quantification of tumour-specific methylation, such as O6-methylguanine-DNA methyltransferase (MGMT) promoter methylation [74,75], a well-established predictor of GBM patient response to alkylating agents like temozolomide (TMZ) [76,77,78].